<DOC>
	<DOCNO>NCT01472185</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel-group , multi-center study determine effect ranolazine give monotherapy glycemic control subject type 2 diabetes mellitus ( T2DM ) inadequately control diet exercise alone treatment naive antihyperglycemic therapy receive antihyperglycemic therapy 90 day ( thiazolidinediones [ TZDs ] least 24 week ) prior screen , characterize relationship HbA1c reduction glycemic parameter subject T2DM .</brief_summary>
	<brief_title>Ranolazine Monotherapy Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Written inform consent Males female , 18 75 year old , inclusive Documented history T2DM Treatment naïve antihyperglycemic therapy receive prior treatment antihyperglycemic therapy least 90 day ( TZDs least 24 week ) prior screen Body mass index ( BMI ) 25 kg/m2 45 kg/m2 inclusive screening HbA1c 7 % 10 % , inclusive screen end Qualifying Period ( Day 14 +2 day ) Fasting serum glucose ( FSG ) ≥ 130 mg/dL ( 7.2 mmol/L ) ≤ 240 mg/dL ( 13.3 mmol/L ) screen end Qualifying Period ( Day 14 +2 day ) . A onetime central laboratory retest FSG allow subject initial central laboratory FSG ≥ 125 mg/dL ( 6.9 mmol/L ) &lt; 130 mg/dL ( 7.2 mmol/L ) otherwise eligible determine investigator . Fasting serum Cpeptide ≥ 0.8 ng/mL screen Able willing comply study procedure course study Females childbearing potential must negative pregnancy test screening must agree use highly effective contraception method screen throughout duration Treatment Period 14 day follow last dose study drug At least 80 % compliant dose Qualifying Period History current diagnosis type 1 diabetes mellitus History diabetic ketoacidosis , ketosisprone diabetes , hyperosmolar hyperglycemic coma History severe episode hypoglycemia ( ≥ 1 episode within 3 month prior screen ≥ 2 episode within 6 month prior screen ) , define hypoglycemia require 3rd party assistance actively administer carbohydrate , glucagon , resuscitative action due severe impairment consciousness behavior Clinically significant complication diabetes , judgment investigator , would make subject unsuitable participate study History clinically significant cardiovascular cerebrovascular event ( eg , myocardial infarction [ MI ] , acute coronary syndrome [ ACS ] , recent coronary revascularization [ include coronary artery bypass graft procedure percutaneous coronary intervention ] , transient ischemic attack ischemic stroke ) ≤ 3 month prior screen Inadequately control unstable hypertension define systolic blood pressure ( SBP ) &gt; 160 mmHg diastolic blood pressure ( DBP ) &gt; 100 mmHg screen randomization Prolonged QTc interval &gt; 500 msec ECG screening , personal family history QTc prolongation , congenital long QT syndrome , subject receive drug prolong QTc interval , Class Ia Class III antiarrhythmic agent , erythromycin , certain antipsychotic ( eg , ziprasidone ) History bariatric surgery time past surgery &lt; 2 month screen , plan undergo surgery study . Subjects plan minor surgery may enrol upon approval Medical Monitor . Any hospitalization 14 day prior screen plan hospitalization time study Significant weight change ( ± 5 % ) &lt; 2 month prior screen weightloss program maintenance phase screen Severe renal impairment , define estimate glomerular filtration rate ( eGFR ) Modification Diet Renal Disease ( MDRD ) equation &lt; 30 mL/min/1.73 m2 screen undergoing type dialysis screen plan undergo type dialysis course study . History liver cirrhosis ( ChildPugh Class A , B C ) Active liver disease and/or significant abnormal liver function define aspartate aminotransferase ( AST ) &gt; 3x upper limit normal range ( ULN ) and/or alanine aminotransferase ( ALT ) &gt; 3x ULN and/or serum total bilirubin &gt; 2.0 mg/dL History cancer ( except nonmelanomic skin cancer cervical situ ) within 5 year prior screen History alcohol drug abuse &lt; 12 month prior screen Any clinically significant exist medical psychiatric condition , include clinically significant laboratory abnormality , one require evaluation , opinion investigator , could interfere conduct study interpretation data Prior treatment openlabel ranolazine know hypersensitivity intolerance ranolazine excipients Treatment strong moderate cytochrome ( CYP ) 3A inhibitor Pglycoprotein ( Pgp ) inhibitor within 14 day prior randomization Treatment CYP3A inducer Pgp inducer within 14 day prior randomization Treatment CYP3A4 substrates narrow therapeutic range ( eg , cyclosporine , tacrolimus , sirolimus ) within 14 day prior randomization Treatment simvastatin daily dose &gt; 20 mg lovastatin daily dose &gt; 40 mg , within 14 day prior randomization Weightloss medication antiobesity medication ( prescription nonprescription ) &lt; 3 month prior screen Treatment niacin &gt; 200 mg daily ; receive ≤ 200 mg daily , stable dos ≥ 90 day prior screen duration study Expected current treatment systemic corticosteroid ( oral injectable ) &gt; 14 day screen end Treatment Period . Topical inhale corticosteroid formulation permit time study If receive thyroid replacement therapy , stable dos least 6 week prior randomization Hemoglobin &lt; 12 g/dL male ; &lt; 11 g/dL female , screen Participation another clinical study involve investigational drug device &lt; 30 day prior screen ; participation another clinical study involve antihyperglycemic therapy &lt; 90 day prior screen Donation blood &lt; 2 month prior screen ; plan donate blood participate study Females pregnant breastfeed Other condition ( ) , opinion investigator , would compromise safety subject , would prevent compliance study protocol ( include ability comply Mixed Meal Tolerance Test [ MMTT ] ) , would compromise quality clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>